Cantex News

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER

Cantex Pharmaceuticals, Inc., announced today that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to Cantex’s azeliragon for the treatment of brain metastasis from breast cancer. This new azeliragon designation adds to azeliragon’s two other Orphan Drug Designations for the treatment of pancreatic cancer and glioblastoma, received...

09 December, 2024

CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING

Cantex Pharmaceuticals announced that azeliragon, a well-tolerated once-a-day pill that inhibits “RAGE” (the receptor for advanced glycation end products), will be featured in four abstracts at this year’s 2024 ASCO Annual Meeting to be held in Chicago....

28 May, 2024

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF PANCREATIC CANCER

Cantex Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Cantex’ azeliragon, a well-tolerated once-a-day pill, for the treatment of pancreatic cancer. ...

20 May, 2024

CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT

Cantex Pharmaceuticals, Inc. announced today that the Company’s CEO, Stephen Marcus, M.D., will be an expert speaker at 5th Annual Glioblastoma Drug Development Summit, which will be held March 26-28 at the Hilton Boston Logan Airport....

19 March, 2024

CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE

Cantex Pharmaceuticals announced that Stephen Marcus, M.D., Chief Executive Officer, is participating in the BIO CEO & Investor Conference and is conducting one-on-one meetings with registered investors, showcasing the Company's business and clinical development strategy, recent corporate achievements, and anticipated milestones....

22 February, 2024

CANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 PIVOTAL CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AZELIRAGON IN THE TREATMENT OF PATIENTS HOSPITALIZED FOR COVID-19

Cantex Pharmaceuticals and Michigan Medicine announced today the initiation of a randomized, double-blind, placebo-controlled, multicenter, Phase 3 pivotal clinical trial to evaluate the safety and efficacy of Cantex’s azeliragon in decreasing the incidence of acute kidney injury and other life-threatening complications in patients hospitalized for COVID-19....

27 September, 2023

Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer

Cantex Pharmaceuticals and Allegheny Health Network (AHN), today announced the initiation of a Phase 1/2 study to assess the safety and efficacy of azeliragon in patients refractory to first-line treatment of metastatic pancreatic cancer....

26 September, 2023

CANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMA

Cantex Pharmaceuticals and Lenox Hill Hospital’s Department of Neurological Surgery announced the initiation of a Phase 2 study to assess the safety and effectiveness of azeliragon in combination with radiation therapy as a treatment for newly diagnosed unmethylated glioblastoma....

18 September, 2023

Cantex Pharmaceuticals Announces Initiation of an Investigator-Initiated Phase 2 Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases

Cantex Pharmaceuticals announced today the initiation of a Phase 2 clinical trial to assess the safety and effectiveness of Cantex’s azeliragon combined with stereotactic radiosurgery in patients with brain metastases. ...

28 August, 2023

Cantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast Cancer

Cantex Pharmaceuticals announced the publication in the peer-reviewed journal, npj Breast Cancer, reporting results from in vitro and in vivo models for triple-negative breast cancer showing suppression of metastasis and tumor progression by RAGE inhibition. Cantex’s azeliragon is a RAGE inhibitor that is orally administered and taken once daily....

10 August, 2023